Compare Abercrombie & Fitch Co. (ANF) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Enveric Biosciences Inc — how do they compare? Abercrombie & Fitch Co. trades at $92.43 (market cap $4.14B), while Enveric Biosciences Inc trades at $1.34 (market cap $5.44M). The key difference: Abercrombie & Fitch Co. is far larger — about 761× Enveric Biosciences Inc's market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ANF | ENVB | |
|---|---|---|
Market Cap | $4.14B | $5.44M |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $17.40 |
52-Week Low | $65.61 | $1.28 |
Enterprise Value | $4.81B | $529.67K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
